Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
R-Pharm
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥20 years
Histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC)
Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage IV, or recurrent
No prior chemotherapy-containing regimens for the treatment of NSCLC
Eastern Cooperative Oncology Group performance status of 0-1
Life expectancy of at least 12 weeks
Accessible for treatment and follow up; patients who could be hospitalized for first 15 days of Cycle 1
Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or radiation therapy)
You may not be if
Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for study period and for up to 4 weeks after last dose of study drug
Women pregnant or breast feeding
Women with a positive pregnancy test result on enrollment or prior to study drug administration
Sexually active fertile men not using effective birth control for the entire study period and for up to 3 months after the last dose of study drug if their partners are WOCBP
Patients with symptomatic or requiring treatment for brain metastases and/or leptomeningeal metastases
Prior radiation must not have included ≥30% of major bone-marrow-containing areas (pelvis, lumbar spine)
Common Terminology Criteria (CTC) Grade 2 or greater neuropathy
Psychiatric or other disorders rendering the patient incapable of complying with protocol requirements
Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix (Patients with a history of malignancy but without evidence of disease for 5 years are eligible)
Serious uncontrolled medical disorder or active systemic infection that would impair the ability of the subject to receive protocol therapy.
Myocardial infarction, unstable angina, or unstable congestive heart failure within 6 months
Known history of infection with human immunodeficiency virus
Inadequate bone marrow function
Inadequate hepatic function
Inadequate renal function
Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents containing Cremophor®EL
Known severe hypersensitivity reaction to agents containing carboplatin and other platinum
Prior treatment with an epothilone and/or with platinum
History of high-dose chemotherapy with bone marrow transplant or peripheral blood stem cell support within 2 years
On treatment with strong Cytochrome P450 3A4 inhibitor
Current imprisonment
Compulsorily detention for treatment of psychiatric or physical illness
Clareo Health | Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer
